Changes To EU Orphan Similarity Concept Could Change Innovation Threshold For 10-Year Exclusivity

The European Commission has proposed changes to the existing criteria used for determining whether a new medicinal product is similar to an already authorized orphan drug and, therefore, whether it can be accepted for evaluation and granted 10-year market exclusivity.